• Qianwen Gao, Xuewu Liang, Abdul Sami Shaikh, Jie Zang, Wenfang Xu, and Yingjie Zhang.
• Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, 44, West Wenhua Road, 250012, Jinan, Shandong, China.
• Curr Drug Targets. 2018 Jan 1; 19 (5): 487-500.

BackgroundJAK/STAT signal pathway, a requisite part in the signaling process of growth factors and cytokines, has become attractive targets for numerous immune, inflammatory and hematopoietic diseases.ObjectiveHerein, we present a review of the JAK/STAT signal pathway, the structure, biological function, mechanism of the JAKs and STATs along with a summary of the up-to-date clinical or approved JAK inhibitors which are involved in the treatment of various kinds of tumors and other immunity indications. Moreover, kinds of recently discovered JAKs inhibitors with potent activity or promising selectivity are also briefly discussed.ConclusionResearch and development of isoform selective JAK inhibitors has become a hot topic in this field. With the assistance of high throughput screening and rational drug design, more and more JAK inhibitors with improved selective profiles will be discovered as biological probes and even therapeutic agents.Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

26 keywords...

hide…